Bayer: presents results of Darolutamide
(CercleFinance.com) - Germany's Bayer has reported that treatment with Darolutamide and androgens significantly increased the overall survival of men with non-metastatic castration-resistant prostate cancer.
Bayer has presented the results of the final ARAMIS Phase III pre-planned overall survival analysis that studied darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
The results showed a statistically significant improvement in overall survival (OS) in patients receiving darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT.
Darolutamide, an oral androgen receptor inhibitor (ARi), has been approved in the United States, Brazil and Japan, and filings in the European Union and other regions are either already underway or planned.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Bayer has presented the results of the final ARAMIS Phase III pre-planned overall survival analysis that studied darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC).
The results showed a statistically significant improvement in overall survival (OS) in patients receiving darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT.
Darolutamide, an oral androgen receptor inhibitor (ARi), has been approved in the United States, Brazil and Japan, and filings in the European Union and other regions are either already underway or planned.
Copyright (c) 2020 CercleFinance.com. All rights reserved.